Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
University of Calgary
$120,000.00
VIVO-EDIT: In Vivo Engineering of Multiplex-Edited CAR-T Cells Using Virus-Like Particles for Cancer Immunotherapy
EF 2025-26
Résumé
Chimeric antigen receptor (CAR)-T cell therapy has demonstrated remarkable effectiveness in treating cancers, achieving 80% response rates in certain patient populations. However, current approaches, which involve removing immune cells from the patient, modifying them in specialized laboratories, and reinfusing them, create significant barriers to patient access and therapeutic durability. The complex manufacturing process requires specialized facilities and prolonged production timelines, resulting in treatment delays that adversely affect patient outcomes. Tragically, even when patients achieve initial remission, 30-60% of patients eventually relapse due to CAR-T cell dysfunction, limiting long-term treatment success. To address these limitations, we have developed VIVO-EDIT, which enables the in vivo generation of multiplex edited CAR-T cells. Our preliminary data demonstrate efficient cell modification along with simultaneous editing of multiple genes that improve cell function and prevent relapse. Importantly, validation in humanized mouse models demonstrated that VLPs selectively target immune cells with minimal off-targets, and achieve stable CAR expression in circulating immune cells comparable to conventional ex vivo CAR-T therapy. This research aims to demonstrate the anti-tumor efficacy of VIVO-EDIT (Aim 1) by testing its ability to eliminate cancer in humanized mouse models of leukemia, directly comparing it to conventional CAR-T cell therapy. We will also establish its safety profile (Aim 2) using mouse models by measuring immune responses to VIVO-EDIT, identifying potential off-target effects and assessing inflammation and toxicity. By eliminating complex manufacturing requirements while enhancing treatment durability, this approach would fundamentally transform the efficiency and accessibility of CAR-T therapy and establish a new paradigm for immune cell engineering, positioning Canada as a leader in next-generation cellular immunotherapy.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
559822
Name
Langley Jethro
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
VIVO-EDIT: In Vivo Engineering of Multiplex-Edited CAR-T Cells Using Virus-Like Particles for Cancer Immunotherapy
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Cancer Therapies; Car-T Cell Therapy; Crispr Technologies; Genome Editing; Immune Cell Engineering; In Vivo Genome Editing; Leukemia; Synthetic Biology; Viral Vectors; Virus-Like Particles
Abstract
Chimeric antigen receptor (CAR)-T cell therapy has demonstrated remarkable effectiveness in treating cancers, achieving 80% response rates in certain patient populations. However, current approaches, which involve removing immune cells from the patient, modifying them in specialized laboratories, and reinfusing them, create significant barriers to patient access and therapeutic durability. The complex manufacturing process requires specialized facilities and prolonged production timelines, resulting in treatment delays that adversely affect patient outcomes. Tragically, even when patients achieve initial remission, 30-60% of patients eventually relapse due to CAR-T cell dysfunction, limiting long-term treatment success. To address these limitations, we have developed VIVO-EDIT, which enables the in vivo generation of multiplex edited CAR-T cells. Our preliminary data demonstrate efficient cell modification along with simultaneous editing of multiple genes that improve cell function and prevent relapse. Importantly, validation in humanized mouse models demonstrated that VLPs selectively target immune cells with minimal off-targets, and achieve stable CAR expression in circulating immune cells comparable to conventional ex vivo CAR-T therapy. This research aims to demonstrate the anti-tumor efficacy of VIVO-EDIT (Aim 1) by testing its ability to eliminate cancer in humanized mouse models of leukemia, directly comparing it to conventional CAR-T cell therapy. We will also establish its safety profile (Aim 2) using mouse models by measuring immune responses to VIVO-EDIT, identifying potential off-target effects and assessing inflammation and toxicity. By eliminating complex manufacturing requirements while enhancing treatment durability, this approach would fundamentally transform the efficiency and accessibility of CAR-T therapy and establish a new paradigm for immune cell engineering, positioning Canada as a leader in next-generation cellular immunotherapy.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Langley, Jethro
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~